| Nome |
# |
|
Proton pump inhibitors: use and misuse in the clinical setting, file e268c4ca-6722-a6b7-e053-3a05fe0adea1
|
1.907
|
|
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications, file e268c4ca-fcf8-a6b7-e053-3a05fe0adea1
|
291
|
|
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease, file e268c4ca-1dbb-a6b7-e053-3a05fe0adea1
|
154
|
|
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered, file e268c4cb-c55c-a6b7-e053-3a05fe0adea1
|
87
|
|
Optimal management of constipation associated with irritable bowel syndrome., file e268c4ca-7d60-a6b7-e053-3a05fe0adea1
|
74
|
|
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV, file e268c4cb-eb3c-a6b7-e053-3a05fe0adea1
|
74
|
|
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data, file e268c4cb-ec49-a6b7-e053-3a05fe0adea1
|
71
|
|
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis, file e268c4ca-1dbd-a6b7-e053-3a05fe0adea1
|
64
|
|
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?, file e268c4cc-7530-a6b7-e053-3a05fe0adea1
|
57
|
|
Latest insights into the hot question of proton pump inhibitor safety – a narrative review, file e268c4cd-1e82-a6b7-e053-3a05fe0adea1
|
44
|
|
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients., file e268c4c6-b0d6-a6b7-e053-3a05fe0adea1
|
6
|
|
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease., file e268c4c6-b0d9-a6b7-e053-3a05fe0adea1
|
6
|
|
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD., file e268c4ca-e9e3-a6b7-e053-3a05fe0adea1
|
5
|
|
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis, file e268c4c8-5211-a6b7-e053-3a05fe0adea1
|
4
|
|
Advancements in the use of manometry and impedance testing for esophageal functional disorders, file e268c4ca-6720-a6b7-e053-3a05fe0adea1
|
4
|
|
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?, file e268c4ca-bf71-a6b7-e053-3a05fe0adea1
|
4
|
|
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations, file e268c4ca-c403-a6b7-e053-3a05fe0adea1
|
4
|
|
A safety review of proton pump inhibitors to treat acid-related digestive diseases, file e268c4ca-c42b-a6b7-e053-3a05fe0adea1
|
4
|
|
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation, file e268c4cc-848a-a6b7-e053-3a05fe0adea1
|
4
|
|
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice, file e268c4cc-9f63-a6b7-e053-3a05fe0adea1
|
4
|
|
Pharmacological management of gastro-esophageal reflux disease: An update of the state-of-the-art, file e268c4ce-6603-a6b7-e053-3a05fe0adea1
|
4
|
|
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis, file e268c4ca-23db-a6b7-e053-3a05fe0adea1
|
3
|
|
Measurement of oro-caecal transit time by magnetic resonance imaging., file e268c4ca-2824-a6b7-e053-3a05fe0adea1
|
3
|
|
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD), file e268c4ca-6732-a6b7-e053-3a05fe0adea1
|
3
|
|
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals, file e268c4ca-77c7-a6b7-e053-3a05fe0adea1
|
3
|
|
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations, file e268c4ca-77c9-a6b7-e053-3a05fe0adea1
|
3
|
|
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn, file e268c4ca-7937-a6b7-e053-3a05fe0adea1
|
3
|
|
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm, file e268c4ca-7af6-a6b7-e053-3a05fe0adea1
|
3
|
|
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease., file e268c4ca-7ce2-a6b7-e053-3a05fe0adea1
|
3
|
|
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients, file e268c4ca-aac5-a6b7-e053-3a05fe0adea1
|
3
|
|
null, file e268c4cb-e9da-a6b7-e053-3a05fe0adea1
|
3
|
|
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice, file e268c4cd-7fe9-a6b7-e053-3a05fe0adea1
|
3
|
|
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose, file 47bf2204-cd0a-40b6-8f31-950c92ff5486
|
2
|
|
Diabetes Medications and Risk of Hepatocellular Carcinoma, file 62fb5a1a-8154-4633-929b-6d0573aafd9e
|
2
|
|
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review, file 7ae9f4ca-2f3c-4078-8de4-a69fab74705d
|
2
|
|
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?, file 7c4932a1-d1af-4073-9d87-e80e2b37e194
|
2
|
|
The appropriate use of proton-pump inhibitors, file e268c4ca-6728-a6b7-e053-3a05fe0adea1
|
2
|
|
Overweight is a risk factor for both erosive and non-erosive reflux disease., file e268c4ca-8017-a6b7-e053-3a05fe0adea1
|
2
|
|
Updates in the field of non-esophageal gastroesophageal reflux disorder, file e268c4ca-e437-a6b7-e053-3a05fe0adea1
|
2
|
|
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease, file e268c4cc-3683-a6b7-e053-3a05fe0adea1
|
2
|
|
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring, file e268c4cd-04ba-a6b7-e053-3a05fe0adea1
|
2
|
|
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?, file e268c4cd-91b6-a6b7-e053-3a05fe0adea1
|
2
|
|
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients, file e268c4ce-0431-a6b7-e053-3a05fe0adea1
|
2
|
|
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach, file e268c4ce-0750-a6b7-e053-3a05fe0adea1
|
2
|
|
Prevention Strategies for Esophageal Cancer—An Expert Review, file e268c4ce-0d07-a6b7-e053-3a05fe0adea1
|
2
|
|
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience, file 19835947-1244-4983-be7f-5d66f2b379de
|
1
|
|
Gastrointestinal Tract Cancers, an Increasing Burden of the Modern Era: Epidemiology and Prevention, file 38479504-0ee5-432d-b7dc-41cc8be16b2a
|
1
|
|
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity, file e268c4c7-aa6e-a6b7-e053-3a05fe0adea1
|
1
|
|
Epidemiology and natural history of gastroesophageal reflux disease, file e268c4ca-1f85-a6b7-e053-3a05fe0adea1
|
1
|
|
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD, file e268c4ca-1f8c-a6b7-e053-3a05fe0adea1
|
1
|
|
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients, file e268c4ca-23d6-a6b7-e053-3a05fe0adea1
|
1
|
|
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index, file e268c4ca-433d-a6b7-e053-3a05fe0adea1
|
1
|
|
Effects of bariatric surgery on the esophagus, file e268c4ca-9fc1-a6b7-e053-3a05fe0adea1
|
1
|
|
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication, file e268c4ca-c137-a6b7-e053-3a05fe0adea1
|
1
|
|
The natural history of gastro-esophageal reflux disease: A comprehensive review, file e268c4ca-c320-a6b7-e053-3a05fe0adea1
|
1
|
|
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients, file e268c4ca-f5b8-a6b7-e053-3a05fe0adea1
|
1
|
|
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope., file e268c4ca-fa68-a6b7-e053-3a05fe0adea1
|
1
|
|
Vonoprazan fumarate for the management of acid-related diseases, file e268c4cb-9441-a6b7-e053-3a05fe0adea1
|
1
|
|
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand, file e268c4cb-c55a-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
2.945 |